# A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.

> **NCT00293163** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 120 (—)

## Conditions studied

- Facial Wrinkles

## Interventions

- **DEVICE:** Hylaform, Hylaform Plus (hylan B gel)

## Key facts

- **NCT ID:** NCT00293163
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 120 (—)
- **Last updated:** 2015-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293163, "A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00293163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*